Product nameAnti-STIL/SIL antibody
See all STIL/SIL primary antibodies
DescriptionRabbit polyclonal to STIL/SIL
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Mouse, Rat
Synthetic peptide corresponding to Mouse STIL/SIL aa 1050-1150 conjugated to keyhole limpet haemocyanin.
(Peptide available as
- This antibody gave a positive signal in the following tissue lysates: Mouse Thymus; Rat Thymus; Mouse Bone Marrow; Mouse Spleen; Rat Spleen.
This product was previously labelled as STIL
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
Storage bufferpH: 7.40
Preservative: 0.02% Sodium azide
Note: Batches of this product that have a concentration < 1mg/ml may have BSA added as a stabilising agent. If you would like information about the formulation of a specific lot, please contact our scientific support team who will be happy to help.
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab124322 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||Use a concentration of 1 µg/ml. Detects a band of approximately 125 kDa (predicted molecular weight: 138 kDa).|
FunctionImmediate-early gene. Plays an important role in embryonic development as well as in cellular growth and proliferation; its long-term silencing affects cell survival and cell cycle distribution as well as decreases CDK1 activity correlated with reduced phosphorylation of CDK1. Play a role as a positive regulator of the sonic hedgehog pathway, acting downstream of PTCH1.
Tissue specificityExpressed in all hematopoietic tissues and cell lines. Highly expressed in a variety of tumors characterized by increased mitotic activity with highest expression in lung cancer.
Involvement in diseaseNote=A chromosomal aberration involving STIL may be a cause of some T-cell acute lymphoblastic leukemias (T-ALL). A deletion at 1p32 between STIL and TAL1 genes leads to STIL/TAL1 fusion mRNA with STIL exon 1 slicing to TAL1 exon 3. As both STIL exon 1 and TAL1 exon 3 are 5'-untranslated exons, STIL/TAL1 fusion mRNA predicts a full length TAL1 protein under the control of the STIL promoter, leading to inappropriate TAL1 expression. In childhood T-cell malignancies (T-ALL), a type of defect such as STIL/TAL1 fusion is associated with a good prognosis. In cultured lymphocytes from healthy adults, STIL/TAL1 fusion mRNA may be detected after 7 days of culture.
Defects in STIL are the cause of microcephaly primary type 7 (MCPH7) [MIM:612703]. Microcephaly is defined as a head circumference more than 3 standard deviations below the age-related mean. Brain weight is markedly reduced and the cerebral cortex is disproportionately small. Despite this marked reduction in size, the gyral pattern is relatively well preserved, with no major abnormality in cortical architecture. Primary microcephaly is further defined by the absence of other syndromic features or significant neurological deficits.
modificationsPhosphorylated following the activation of the mitotic checkpoint.
Cellular localizationCytoplasm > cytosol.
- Information by UniProt
- DKFZp686O09161 antibody
- MCPH7 antibody
- OTTHUMP00000009566 antibody
All lanes : Anti-STIL/SIL antibody (ab124322) at 1 µg/ml
Lane 1 : Thymus (Mouse) Tissue Lysate
Lane 2 : Thymus (Rat) Tissue Lysate
Lane 3 : Mouse Bone Marrow Tissue Lysate
Lane 4 : Spleen (Mouse) Tissue Lysate
Lane 5 : Spleen (Rat) Tissue Lysate
Lysates/proteins at 10 µg per lane.
All lanes : Goat Anti-Rabbit IgG H&L (HRP) preadsorbed (ab97080) at 1/5000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 138 kDa
Observed band size: 125 kDa why is the actual band size different from the predicted?
Additional bands at: 14 kDa. We are unsure as to the identity of these extra bands.
Exposure time: 8 minutes
ab124322 has not yet been referenced specifically in any publications.